Skip to main content
. 2024 Dec 5;33(1):170–181. doi: 10.4062/biomolther.2024.069

Fig. 2.

Fig. 2

Low-dose perifosine exerts minimally sensitizes normal human HaCaT cells. (A) MCF-7/ADR cells were treated with 5 nM VIC, 5 μM perifosine (PERI-5μM), 10 μM perifosine (PERI-10μM), or 0.1% DMSO (CON). After 24 h, annexin V analyses were performed as described in Materials and Methods. (B) MCF-7/ADR cells were treated with 5 μM perifosine (PERI), 10 μM GSK690693, or 0.1% DMSO (CON). After 2 day, all cells were also observed using an inverted microscope at ×40 magnification, and annexin V analyses were performed as described in Materials and Methods. (C, D) HaCaT cells were treated with 5 nM VIC, 5 μM perifosine (PERI-5μM), 10 μM perifosine (PERI-10μM), 1 μM BKM120, 10 μM AZD5363, 10 μM GSK690693, or 0.1% DMSO (CON). After 24 h, annexin V analyses were performed as described in Materials and Methods. AZD5363-, GSK690693- or DMSO (CON)-treated cells were also observed using an inverted microscope at ×40 magnification. (E) HaCaT cells were grown on 60 mm-diameter dishes with high density (upper) or low density (lower). They were then treated with 5 nM VIC, 5 μM perifosine (PERI), or 0.1% DMSO (CON). After 1 day, all cells were observed using an inverted microscope at ×40 magnification. (F) MCF-7/ADR, MCF-7, or HaCaT cells were treated with 10 μM MK-2206, or 0.1% DMSO (CON). After 1 day, all cells were observed using an inverted microscope at ×40 magnification.